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syndromes, one subcutaneous hemorrhage leading to an 
abscess in the abdominal wall, and one metastasis at the 
PEG site. The most common minor complication was peri-
stomal granulomatous tissue affecting 23 (18.5%) patients. 
After the change in practice, median time delay before 
PEG insertion decreased from 13 to 10 days (P < 0.005). 
The proportion of early PEG placements within 0–3 days 
increased from 3.6 to 14.6% (P < 0.005). PEG tube insertion 
seems to be a safe procedure in the hands of an ORL-HN 
surgeon. Independence from gastrointestinal surgeons’ ser-
vices reduced the time delay and improved the availability 
of urgent PEG insertions.
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Introduction
Percutaneous endoscopic gastrostomy (PEG) is often the 
treatment of choice to prevent malnutrition in patients with 
prolonged dysphagia. Patients with head and neck cancer 
(HNC) sometimes require enteral feeding with PEG, because 
the disease itself, treatment, or its side effects may impair 
oral intake and compromise nutritional status.
Departments of Otorhinolaryngology—Head and Neck 
Surgery (ORL-HNS) usually coordinate and are respon-
sible for the management of HNC. Although PEG inser-
tions are typically carried out in the units of gastrointestinal 
surgery, performing them in ORL-HNS centers provides 
advantages both for patients and for health-care providers. 
These advantages include: (1) cost-effectiveness in terms 
of performing tube placement simultaneously with other 
procedures included in pre-treatment work-up or treatment; 
(2) logistic advantages; (3) minimization of delays; and (4) 
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simplification of the treatment process. In several developed 
countries, otorhinolaryngologists—head and neck (ORL-
HN) surgeons—insert PEG tubes for patients with HNC 
[1], but only nine retrospective studies from four countries 
have evaluated the outcome of such practice [2–10]. None of 
them, however, analyzed time gains achieved by independ-
ence in practice.
ORL-HN surgeons have performed all PEG tube inser-
tions for HNC patients at the Helsinki University Hospi-
tal, Department of ORL-HNS, since 2008. During the first 
two years after the introduction of the procedure at our 
department, the process was validated by comparing the 
outcome of PEG insertions with that of the Department of 
Gastrointestinal Surgery [3]. The aim of this study was to 
evaluate changed practice and the complications of PEG 
tube placements in a prospective setting. We also analyzed 
current time delay in PEG tube insertions and compared 
that with our earlier practice, where patients needing PEG 
were referred to the Department of Gastrointestinal Surgery.
Patients and methods
Our prospective study of HNC patients undergoing PEG 
tube placement at the Department of ORL-HNS, Helsinki 
University Hospital, Helsinki, Finland, took place between 
October 2011 and May 2013. Demographic data, tumor 
characteristics, indication for PEG tube insertion, time 
interval between the decision for PEG and the insertion, and 
details of the procedure were available for 127 consecutive 
patients. ORL-HN surgeons specialized to surgical oncol-
ogy and trained to execute the procedure performed all PEG 
insertions.
We retrospectively reviewed a separate group of 110 
HNC patients referred from our department to the Depart-
ment of Gastrointestinal Surgery, Helsinki University Hos-
pital, for PEG tube placement between 2005 and 2008. This 
enabled us to assess possible time gains and reduction of 
delays achieved by adopting this new practice of PEG inser-
tions by ORL-HN surgeons.
The Research Ethics Board approved the study (DNRO 
89/13/03/02/2011), and patients provided their written 
informed consent. The study was registered at ClinicalTri-
als.gov with identifier NCT02937610.
All patients, except for two with ongoing antibiotic treat-
ment, received a single dose of preoperative intravenous 
antibiotic prophylaxis (Cefuroxime 1.5 g). The  MIC® PEG 
kit of 20 French (Kimberly-Clark, Zaventum, Belgium) was 
used for all patients. The PEG placements were carried out 
with a pull-through technique [11] with two ORL-HN sur-
geons involved each time. Postoperatively, a trained nurse 
instructed all patients how to maintain and use the PEG 
tube, and three to five days after the placement loosened the 
external bumper during an outpatient visit. Patients were 
instructed to contact the nurse directly for any problems aris-
ing with the PEG tube.
When the patient was able to maintain body weight 
with oral nutrition only, and when no further treatment that 
would impact oral intake was scheduled, the PEG tube was 
removed. Any complications occurring within a year of the 
PEG placement were recorded, as were data on any PEG 
tube removal or patient’s death. The complications were 
divided into minor and major according to Grant et al. [12]. 
After the follow-up period, we reviewed the medical charts 
and verified and completed all essential data.
Statistical analyses were performed with the SPSS soft-
ware  (IBM®  SPSS® Statistics Version 21.0, Armonk, NY). 
The normality of data distribution was evaluated visually 
using histograms and with Skewness and Kurtosis measures. 
Comparisons of time delay between groups were performed 
with Mann–Whitney U and Pearson χ2 tests. A two-sided P 
value of <0.05 was regarded as statistically significant.
Results
In the cohort of 127 HNC patients referred for PEG tube 
insertion during the study period, the success rate was 
97.6%. Insertion failed in three patients: one had severe 
trismus, and in two cases, reliable determination of a proper 
site for the PEG on the abdominal wall was not possible. 
The final study group thus comprised 124 patients with a 
mean age of 61 (range 31–89) years and male predominance 
(76.6%). Mean body mass index before PEG tube placement 
was 25.0 (range 13.2–39.2).
The most common site of the primary tumor was oro-
pharynx (43.5%), followed by oral cavity (24.2%; Table 1). 
The disease was locally advanced (Stage III–IV) in 84.7% 
of the patients. The majority received oncological treatment, 
as the definitive treatment was chemoradiotherapy for 67 
(54.0%) patients and surgery combined with radiotherapy for 
43 (34.7%) patients. The PEG tube was placed prophylacti-
cally in 95 (76.6%) cases. Other procedures were performed 
simultaneously for 21 (17.9%) patients.
Altogether, 47 (37.9%) patients experienced 51 compli-
cations (Table 2). Minor complications affected 43 (34.7%) 
patients: four of them suffered from two separate complica-
tions. Peristomal granulomatous tissue was the most com-
mon minor complication affecting 23 (18.5%) patients.
Four (3.2%) patients suffered major complications. 
Two had buried bumper syndrome (PEG tube’s internal 
bumper migration into the gastric wall). One patient expe-
rienced a major postoperative subcutaneous hemorrhage 
on the fourth postoperative day. This led to an abscess and 
necrosis in the abdominal wall and caused considerable 
discharge of stomach contents, warranting laparotomy at 
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the Department of Gastrointestinal Surgery. A 50-year-
old man with T2N2M0 epidermoid carcinoma in the 
base of his tongue developed an implantation metastasis 
at the PEG site five months after PEG tube placement. 
The metastasis was resected, but thereafter, he developed 
additional metastases during follow-up in the abdominal 
wall, omentum, and lungs, and he died 14 months after the 
diagnosis of the original implantation metastasis.
No deaths occurred during the first week after the pro-
cedure. One patient died from underlying liver cirrhosis 
18 days after PEG tube placement, leading to a 30-day mor-
tality rate of 0.8%. One-year mortality rate was 21.0% (26 
patients out of 124). At the time of death, the PEG tube 
was still in place in 22 (84.6%) patients. PEG tube had 
been removed from 81 (82.7%) and was still in place in 17 
(17.3%) out of the 98 patients alive at the one-year follow-
up. Median time from tube placement to its removal was 
130 days (range 41–327).
Figure 1 illustrates the time interval between the deci-
sion for PEG insertion and the procedure in the present 
prospective study population and in HNC patients who had 
received their PEG tubes at the Department of Gastrointes-
tinal Surgery before PEG insertions began at our department 
(median for study patients, 10 days; for reference group, 
13 days; P = 0.002). The proportion of early PEG insertions 
was higher in the study population (14.6 vs. 3.6% within 
0–3 days; P = 0.004; and 24.4 vs. 14.5% within 4–6 days; 
P = 0.06).
Discussion
We found PEG placement to be a safe procedure in the ORL-
HNS service, with only a few major complications and no 
procedure-related mortality. Transferring the practice of 
PEG insertions from gastrointestinal surgeons to ORL-HN 
surgeons saved time and allowed more prompt response 
to urgent need for nutritional support. All other reports 
addressing the outcome of PEG tube placements performed 
by otorhinolaryngologists are retrospective, with no data on 
the benefits regarding time gains. Our study on 124 consecu-
tive HNC patients introduced with PEG at our department 
Table 1  Tumor characteristics and treatment details for 124 patients 
(%)
BMI body mass index
a Data missing in five patients. bSimultaneous tracheostomy and 
biopsy for six patients, simultaneous tracheostomy and definitive sur-
gery for one patient, and simultaneous tracheostomy and cricopharyn-
geal bar dilatation for one patient
Site of primary tumor
 Oropharynx 54 (43.5)














Nodal metastases 90 (72.6)








 Surgery and radiotherapy 43 (34.7)
 Radiotherapy 8 (6.5)
 Surgery 5 (4.0)
Timing of PEG tube placement
 Before treatment 95 (76.6)
 During treatment 28 (22.6)
 After treatment 1 (0.8)
Simultaneous other  procedureb 23 (18.5)
 Tracheotomy 12 (9.7)
 Biopsy 10 (8.1)
 Definitive surgery 6 (4.8)
Other procedure 3 (2.4)
Table 2  Complications in a cohort of 124 patients (%)
PEG percutaneous endoscopic gastrostomy
Minor
 Peristomal granulation 23 (18.5)
 Peristomal infection 8 (6.5)
 Discharge of PEG 6 (4.8)
 PEG tube occlusion 4 (3.2)
 Local hemorrhage 3 (2.4)
 Minor abscess 2 (1.6)
 Late extrusion of the PEG tube 1 (0.8)
Major
 Buried bumper 2 (1.6)
 Major hemorrhage 1 (0.8)
 Implantation metastasis 1 (0.8)
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between 2011 and 2013 has the advantages of its prospec-
tive nature.
Our rate of successful PEG insertion (97.6%) is consistent 
with other published series of HNC patients, where failure 
rates vary between 0 and 9% [5, 9, 12–16]. Reported rates 
of minor complications associated with PEG tube place-
ment range from 0 to 35% and those of major complications 
between 0 and 8% [3, 5, 12–14, 17–19]. Our major compli-
cation rate of 3.2% compares favorably with the correspond-
ing results reported elsewhere. Our relatively high incidence 
of minor complications (34.7%) can in part have resulted 
from the prospective recording in this study. Furthermore, 
granulation at the stoma site might be considered an accept-
able problem related to PEG use, and is not reported as a 
complication in most publications. We included it among 
the reported events to determine its incidence; this allows us 
to offer our future patients’ accurate information regarding 
any possible problems with PEG.
Metastatic spread of squamous cell carcinoma to the PEG 
site in HNC patients is a rare but recognized complication 
[20–24]. Direct traumatic seeding is the leading hypothesis 
regarding early PEG-site metastases [21], whereas metas-
tases after 12 months may ensue from spontaneous inter-
mittent tumor shedding from the primary tumor along the 
gastrointestinal tract, or from systemic spread [20, 23]. In 
the current series, PEG-site metastasis developed in only 
one (0.8%) patient, which is in line with reported inci-
dences of 0.5–1% [2, 25, 26]. Risk of metastatic seeding 
can be reduced by shielding the tumor during procedure, and 
avoided with using open or radiologically inserted gastros-
tomy (RIG) [20, 22, 27]. At our institution, availability of 
RIG is limited and open gastrostomy is a method of choice 
for patients with failure or anticipated failure of PEG.
PEG placement is recommended only in cases in which 
the expected need for tube feeding exceeds 30 days [28]. 
Thus, death or removal of the PEG within a month from 
insertion can be considered a failure in patient selection. A 
study by Ehrsson et al. [13] reported a 28-day mortality or 
removal rate of 10.5% in their HNC population, and Poulose 
et al. [29] a 30-day mortality of 5% in the subgroup with 
HNC. In mixed patient populations, 30-day mortality rates 
after PEG placements range from 2.4 to 22% [30–35]. In 
the present study, only one patient died, and no tubes were 
removed within 30 days after the procedure, reflecting high 
success in patient selection. At our department, every deci-
sion to insert PEG is discussed at a multidisciplinary tumor 
board meeting, and we follow internationally approved 
guidelines for the use of enteral nutrition [28].
Malnutrition in cancer patients is associated with slower 
recovery, prolonged hospital stay, and worse prognosis [36]. 
Therefore, maintaining and improving patient’s nutritional 
status before, during, and after HNC treatment provides sev-
eral benefits for the patient [37, 38]. Controversy remains 
regarding the optimal time for PEG placement. The literature 
supports the advantages of prophylactic PEG to enhance bet-
ter quality of life with less aspiration, fewer strictures, infre-
quent hospitalizations, and uninterrupted chemoradiotherapy 
[39–42], whereas other studies have failed to confirm many 
benefits from prophylactic versus reactive nutrition through 
PEG [43, 44]. Moreover, there is concern about the impact 
of prophylactic PEG insertion on swallowing function as 
some studies have suggested that this practice may reduce 
patient’s motivation to continue oral intake and thus lead to 
increased risk of dysphagia [45, 46]. A recent systematic 
review, however, addressed long-term outcomes in swallow-
ing after prophylactic PEG tube placement in HNC patients 
and resulted with no consensus [47]. Our rate of prophylac-
tic PEG placements was 76.6%. We follow strict criteria in 
patient selection, and the optimal timing for initiating the use 
of the tube is evaluated individually for each patient. We also 
strongly encourage our patients to continue oral nutrition 
with at least water on a regular basis.
As head and neck surgeons play the leading role in pro-
viding diagnostics and coordinating care for patients with 
HNC, implementing PEG tube placement to the ORL-HN 
oncological surgeon’s tool kit seems beneficial. The fea-
sibility of PEG insertion in the hands of a head and neck 
surgeon is a topic of interest [2–10]. The possibility of plac-
ing PEG tube for HNC patient simultaneously with other 
Fig. 1  Time interval between the decision for PEG and the insertion. 
Comparison of prospective study patients with a retrospective cohort 
of HNC patients referred to the Department of Gastrointestinal Sur-
gery between 2005 and 2008
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interventions is clearly beneficial. Additional endoscopies, 
biopsies, tracheotomy, and dental procedures are easily com-
bined with PEG insertion. Even when other simultaneous 
procedures are not required, sedation during PEG insertion 
may be exploited to perform comprehensive physical exam-
ination or specific surgical planning. HNC patients often 
experience pain which may hinder performing comprehen-
sive status in outpatient clinic. In our series, other proce-
dures were performed for only 17.9% of patients. The major-
ity of diagnostic endoscopies and biopsies at our department 
take place in a consulting room under local anesthesia. Fur-
thermore, a high proportion of patients treated without any 
surgical interventions (60.5%) restricts combining PEG with 
definitive surgery. However, in the future, we will focus upon 
exploiting the benefits of simultaneously performed other 
procedures.
Since 2008, logistics concerning the management of HNC 
patients at the Helsinki University Hospital have become 
more straightforward, because we have omitted a PEG-inser-
tion visit to the Department of Gastrointestinal Surgery from 
our treatment protocol. Timing of the operation is easier to 
adjust with the many other visits to health care that these 
patients require. In addition, centralizing the treatment to 
one unit and commonly to one physician reduces the burden 
and stress for the patient and their family. Anesthetists and 
nursing staff are accustomed to this special patient group, 
which increases the safety of the procedure and enables 
efficient follow-up. We demonstrated that independence 
from other specialties regarding this procedure has reduced 
median time delay from decision to procedure at our unit by 
a few days, which is highlighted especially in patients who 
are malnourished at the time of diagnosis and who may need 
instant nutritional support. Nutritional compromise hinders 
therapy completion, impacts survival, and impairs post-treat-
ment quality of life of HNC patients despite the definitive 
treatment modality [48, 49]. Every effort to avoid any delay 
in nutritional intervention is, therefore, an essential part of 
optimizing HNC treatment.
Conclusions
Sufficient nutritional supply is essential in the management 
of patients with HNC. We demonstrate that when nutritional 
support is required, a PEG tube can be safely and success-
fully inserted by ORL-HN oncological surgeons. In this pro-
spective study, major complications after PEG tube place-
ment were rare, but minor problems at stoma site appeared 
frequently. Therefore, emphasizing accurate stoma care in 
patient counseling is necessary. The number of unnecessary 
PEG tube placements can be minimized with careful patient 
selection. Adding PEG tube insertion to the ORL-HN sur-
geon armamentarium should reduce the delay in PEG tube 
placement and simplify HNC patients’ treatment process. 
We suggest that PEG placement should be implemented as 
a part of the training of ORL-HN oncological surgeons.
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